Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1–deficient malignant pleural mesothelioma: a randomized …
PW Szlosarek, JP Steele, L Nolan, D Gilligan… - JAMA …, 2017 - jamanetwork.com
Importance Preclinical studies show that arginine deprivation is synthetically lethal in
argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role
of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not been
evaluated in a randomized and biomarker-driven study among patients with cancer.
Objective To assess the clinical impact of arginine depletion in patients with ASS1-deficient
malignant pleural mesothelioma. Design, Setting, and Participants A multicenter phase 2 …
argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role
of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not been
evaluated in a randomized and biomarker-driven study among patients with cancer.
Objective To assess the clinical impact of arginine depletion in patients with ASS1-deficient
malignant pleural mesothelioma. Design, Setting, and Participants A multicenter phase 2 …